{"id":"melphalan-mel","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"20-40","effect":"Mucositis"},{"rate":null,"effect":"Secondary malignancy"},{"rate":null,"effect":"Infertility"},{"rate":"10-20","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":{"setId":"e9c2efee-173d-4795-96d8-7aae5b3a3073","title":"MELPHALAN (MELPHALAN HYDROCHLORIDE) KIT [FRESENIUS KABI USA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Melphalan belongs to the nitrogen mustard class of alkylating agents. It forms covalent bonds with DNA bases, creating interstrand and intrastrand cross-links that interfere with DNA replication and transcription. This leads to cell cycle arrest and apoptosis, particularly affecting rapidly dividing cancer cells.","oneSentence":"Melphalan is an alkylating agent that cross-links DNA strands, preventing cell division and causing cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:00:19.661Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Light chain amyloidosis"},{"name":"Waldenström macroglobulinemia"}]},"trialDetails":[{"nctId":"NCT07396480","phase":"PHASE3","title":"Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-03-01","conditions":"Venentoclax, Myeloid Malignancies, Conditioning","enrollment":186},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT07029776","phase":"PHASE2","title":"MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"University of Arkansas","startDate":"2026-07-01","conditions":"Multiple Myeloma (MM)","enrollment":50},{"nctId":"NCT03579875","phase":"PHASE2","title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2018-11-13","conditions":"Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes","enrollment":48},{"nctId":"NCT03159702","phase":"PHASE2","title":"Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-12-08","conditions":"Hematological Malignancy, Multiple Myeloma","enrollment":43},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT04191187","phase":"PHASE2","title":"Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-12-06","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia","enrollment":34},{"nctId":"NCT03016806","phase":"","title":"Umbilical Cord Blood Transplantation From Unrelated Donors","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2015-06","conditions":"Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder","enrollment":30},{"nctId":"NCT07025824","phase":"PHASE2","title":"Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Technische Universität Dresden","startDate":"2025-09","conditions":"AML - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome)","enrollment":220},{"nctId":"NCT05735717","phase":"PHASE2","title":"MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-05-11","conditions":"Hematologic Malignancy, Acute Leukemia, Remission","enrollment":70},{"nctId":"NCT07078721","phase":"PHASE2","title":"Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-07-20","conditions":"Aplastic Anemia Idiopathic","enrollment":11},{"nctId":"NCT00871013","phase":"PHASE2","title":"Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2009-03","conditions":"Myeloma","enrollment":160},{"nctId":"NCT00869232","phase":"PHASE2","title":"UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-10","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT00734877","phase":"PHASE3","title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":382},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT01350258","phase":"PHASE1, PHASE2","title":"Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-04","conditions":"Hematologic Malignancies, Acute Leukemia, Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes","enrollment":8},{"nctId":"NCT02988466","phase":"PHASE2","title":"Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-01-24","conditions":"Hematologic Malignancies","enrollment":78},{"nctId":"NCT06125483","phase":"NA","title":"TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-11-01","conditions":"Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation","enrollment":38},{"nctId":"NCT01163357","phase":"PHASE1","title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2011-01-28","conditions":"Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia","enrollment":18},{"nctId":"NCT02506959","phase":"PHASE2","title":"Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma","enrollment":83},{"nctId":"NCT06879847","phase":"NA","title":"A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-01","conditions":"Relapsed or Refractory Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT06548958","phase":"NA","title":"A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-07-10","conditions":"Malignant Hematological Diseases","enrollment":40},{"nctId":"NCT05991908","phase":"PHASE3","title":"Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2023-10-19","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":222},{"nctId":"NCT03187223","phase":"PHASE2","title":"Bendamustine and Melphalan in Myeloma","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2017-07-20","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT02043847","phase":"PHASE1","title":"TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2014-01-14","conditions":"Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment","enrollment":12},{"nctId":"NCT06602323","phase":"PHASE2","title":"TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome or Acute Myeloid Leukemia.","status":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-01","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT06571825","phase":"PHASE4","title":"RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR","status":"RECRUITING","sponsor":"He Huang","startDate":"2024-07-17","conditions":"Acute Myeloid Leukemia","enrollment":118},{"nctId":"NCT05636787","phase":"PHASE2","title":"Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-06-06","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT03292263","phase":"PHASE1, PHASE2","title":"ASCT With Nivolumab in Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2017-04-24","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT06247917","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDS","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2024-03-03","conditions":"Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome With Excess Blasts-2, Myelodysplastic Syndromes","enrollment":59},{"nctId":"NCT06133556","phase":"PHASE2","title":"Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-11-24","conditions":"Acute Myeloid Leukemia","enrollment":237},{"nctId":"NCT04269811","phase":"PHASE2","title":"Flu-Bu-Mel Conditioning Regimen for Myeloid Disease","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-01-15","conditions":"Relapse Rate After Allo-HSCT","enrollment":49},{"nctId":"NCT04897139","phase":"PHASE2","title":"Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-01-01","conditions":"Lymphoid Neoplasm","enrollment":23},{"nctId":"NCT01907009","phase":"PHASE2, PHASE3","title":"A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP)","status":"TERMINATED","sponsor":"Barts & The London NHS Trust","startDate":"2013-01","conditions":"Castrate Resistant Prostate Cancer","enrollment":29},{"nctId":"NCT05814718","phase":"NA","title":"Modified BEAM Regimen for T Cell Lymphoma Underwent ASCT","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-04-15","conditions":"Autologous Stem Cell Transplantation, Conditioning","enrollment":122},{"nctId":"NCT01339910","phase":"PHASE3","title":"Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2011-06","conditions":"Leukemia, Myelocytic, Acute","enrollment":272},{"nctId":"NCT01410344","phase":"PHASE2","title":"Allogeneic Transplant in HIV Patients (BMT CTN 0903)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2011-09","conditions":"Leukemia, Lymphoma, HIV","enrollment":20},{"nctId":"NCT03852407","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning","status":"RECRUITING","sponsor":"University of Liege","startDate":"2019-02-04","conditions":"Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia in Remission","enrollment":114},{"nctId":"NCT01078454","phase":"PHASE3","title":"Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11","conditions":"Light Chain Deposition Disease, Primary Systemic Amyloidosis","enrollment":11},{"nctId":"NCT02128230","phase":"PHASE2","title":"UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2014-06-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT02181478","phase":"EARLY_PHASE1","title":"Intra-Osseous Co-Transplant of UCB and hMSC","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-07-22","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes","enrollment":6},{"nctId":"NCT02750254","phase":"PHASE1","title":"Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2016-06-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia","enrollment":5},{"nctId":"NCT03385096","phase":"PHASE2, PHASE3","title":"Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-01-02","conditions":"Autologous Hematopoietic Stem Cell Transplantation, Conditioning, Multiple Myeloma","enrollment":122},{"nctId":"NCT02589145","phase":"PHASE1, PHASE2","title":"Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06-22","conditions":"Lymphoma","enrollment":8},{"nctId":"NCT03100877","phase":"PHASE1, PHASE2","title":"Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2018-01","conditions":"Plasma Cell Leukemia in Remission, Plasma Cell Myeloma","enrollment":""},{"nctId":"NCT00083915","phase":"PHASE3","title":"DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-06","conditions":"Multiple Myeloma","enrollment":97},{"nctId":"NCT02981199","phase":"NA","title":"Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"Chen Wenming","startDate":"2016-01","conditions":"Microtransplantation, Autologous Stem Cell Transplantation, Multiple Myeloma in Relapse","enrollment":80},{"nctId":"NCT02447055","phase":"EARLY_PHASE1","title":"Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2015-12","conditions":"Multiple Myeloma, Myeloma-Multiple","enrollment":""},{"nctId":"NCT00892346","phase":"PHASE3","title":"Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma","status":"SUSPENDED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-05","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT02701673","phase":"PHASE1, PHASE2","title":"Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-06","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00800150","phase":"PHASE1","title":"Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2008-11","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":6},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT01055301","phase":"PHASE2","title":"S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2011-07","conditions":"Multiple Myeloma, Plasma Cell Myeloma","enrollment":""},{"nctId":"NCT00002548","phase":"PHASE3","title":"SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1994-01","conditions":"Multiple Myeloma","enrollment":899},{"nctId":"NCT00189488","phase":"PHASE2","title":"Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-12","conditions":"Graft Versus Host Disease, Hematologic Malignancies","enrollment":155},{"nctId":"NCT02114502","phase":"PHASE2","title":"Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-09","conditions":"Myeloma","enrollment":""},{"nctId":"NCT00883623","phase":"PHASE2","title":"A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis","status":"COMPLETED","sponsor":"Heidelberg University","startDate":"2009-04","conditions":"Primary Amyloidosis","enrollment":50},{"nctId":"NCT01665014","phase":"PHASE2","title":"Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma","status":"UNKNOWN","sponsor":"Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice","startDate":"2012-08","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT00577668","phase":"PHASE2","title":"A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2007-04","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT00772811","phase":"PHASE2","title":"Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma","status":"COMPLETED","sponsor":"Cooperative Study Group A for Hematology","startDate":"2001-07","conditions":"Chronic Lymphocytic Leukemia, Lymphoma, Multiple Myeloma","enrollment":38},{"nctId":"NCT00275678","phase":"PHASE3","title":"Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2003-11","conditions":"Blood Stem Cell Transplant","enrollment":15},{"nctId":"NCT00804947","phase":"PHASE2","title":"Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen","status":"UNKNOWN","sponsor":"Fundacion Para La Investigacion Hospital La Fe","startDate":"2005-09","conditions":"Multiple Myeloma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":178,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["L-PAM"],"phase":"marketed","status":"active","brandName":"Melphalan (Mel)","genericName":"Melphalan (Mel)","companyName":"Institute of Hematology & Blood Diseases Hospital, China","companyId":"institute-of-hematology-blood-diseases-hospital-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Melphalan is an alkylating agent that cross-links DNA strands, preventing cell division and inducing apoptosis in rapidly dividing cancer cells. Used for Multiple myeloma, Light chain amyloidosis, Waldenström macroglobulinemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}